Renal Cell Carcinoma Clinical Trial
Official title:
A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC- 7366 in Combination With Belzutifan (WELIREG™) in Patients With Locally Advanced (Inoperable) or Metastatic Renal Cell Carcinoma
This is a Phase 1b, open-label, multicenter, safety, tolerability and efficacy study of HC-7366 in combination with belzutifan (WELIREG™). This is a multipart study that consists of a HC-7366 monotherapy cohort, a combination dose escalation, and a combination dose expansion. Approximately 80 patients will be enrolled in this study (up to 20 patients will be enrolled into the HC-7366 monotherapy cohort, up to 30 patients into the combination dose escalation, and up to 30 patients into the combination dose expansion). The primary purpose of this study is to determine the maximum tolerated dose of HC-7366 in combination with belzutifan in patients with locally advanced (inoperable) or metastatic RCC with predominantly clear cell histology, irrespective of VHL gene mutation status.
Status | Recruiting |
Enrollment | 80 |
Est. completion date | November 2027 |
Est. primary completion date | November 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Has diagnosis of locally advanced (inoperable) or metastatic RCC with a predominant clear cell component - Be age 18 years or older (male or female) at the time of consent - Patients with progressive disease after receipt of at least 2 and no more than 5 prior lines of therapy for metastatic (stage IV) disease, including but not limited to VEGF-directed tyrosine kinase inhibitors (TKIs), high-dose IL-2, immune checkpoint inhibitors, or Mtor inhibitors alone or in combination. - Has adequate organ function - Has ECOG performance score of 0-1 - Has at least one measurable lesion as per RECIST 1.1. - Has a life expectancy of 3 months or greater as determined by the treating physician. Exclusion Criteria: - Has received prior treatment with belzutifan or another HIF-2a inhibitor - Has received any type of small molecule kinase inhibitor (including investigational kinase inhibitor) =2 weeks before allocation. - Has received any type of systemic anticancer antibody (including investigational antibody) =4 weeks before allocation. - Has participated in a study of an investigational agent and received study therapy within 4 weeks of the first dose of treatment - Has had history of major surgery < 3 weeks before allocation - Has received prior radiotherapy within 2 weeks before allocation - Have clinically significant cardiovascular disease within 6 months from first dose of study drug administration - Has known additional malignancy that is progressing or required active treatment within the past 5 years - Has a history of or known active central nervous system metastases and/or carcinomatous meningitis - Is unable to swallow orally administered medication intact or has a history or current evidence of a gastrointestinal disorder - Has known human immunodeficiency virus (HIV) and/or hepatitis B or C infections - Has a history of or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, or interfere with the individual's ability to cooperate with the requirements of the study - Is pregnant or breastfeeding or expecting to conceive children within the projected duration of the study, starting with the screening visit through 90 days after the final administration of the study drug. |
Country | Name | City | State |
---|---|---|---|
United States | University of California San Diego Moores Cancer Center | La Jolla | California |
United States | Rocky Mountain Cancer Centers, LLP | Lone Tree | Colorado |
United States | SCRI Oncology Partners | Nashville | Tennessee |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
United States | Washington University School of Medicine | Saint Louis | Missouri |
United States | HealthPartners Cancer Research Center | Saint Paul | Minnesota |
Lead Sponsor | Collaborator |
---|---|
HiberCell, Inc. | Merck Sharp & Dohme LLC |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Determination of MTD and RP2D (combination cohorts only) | To identify the maximum tolerated dose (MTD) and/ or recommended Phase 2 dose (RP2D), and evaluate the safety, tolerability and dose-limiting toxicities (DLTs) of HC-7366 in combination with belzutifan in patients with locally advanced (inoperable) or metastatic RCC with predominantly clear cell histology irrespective of VHL gene mutation status | Approximately 30 months | |
Primary | Occurrence of dose limits toxicities in the dose-escalation period | Approximately 30 months | ||
Primary | Number of participants who experience treatment-emergent adverse events (TEAEs) and treatment-related TEAEs and the severity of these events | Approximately 30 months | ||
Primary | Number of participants who experience TEAEs leading to premature discontinuation | Approximately 30 months | ||
Primary | Number of participants who experience laboratory abnormalities | Approximately 30 months | ||
Primary | Number of participants who experience abnormalities observed in 12-lead ECG parameters. | Approximately 30 months | ||
Primary | Number of participants who experience abnormalities observed in vital signs measurements. | Number of participants who experience abnormalities observed in vital signs measurements. | Approximately 30 months | |
Secondary | Overall response rate (ORR): percentage of participants who achieved documented complete response (CR) + confirmed partial response (PR) per RECIST Version 1.1 | Approximately 30 months | ||
Secondary | Duration of response (DOR): time from first response (CR or PR) to the date of progression or death from any cause, whichever occurs first per RECIST Version 1.1 | Approximately 30 months | ||
Secondary | Time to response (TTR): time from first dose to first documented response | Approximately 30 months | ||
Secondary | Progression-free survival (PFS) and PFS at 6 months: time from first dose to documented disease progression or death due to any cause, whichever occurs first per RECIST Version 1.1 | Approximately 30 months | ||
Secondary | Median overall survival (OS) and 1-yr OS: time from the first day of study intervention to death due to any cause | Approximately 30 months | ||
Secondary | Area under the plasma concentration versus time curve from time 0 until the last measurable concentration (AUC 0-last [ng·hr/mL]) | Approximately 30 months | ||
Secondary | Area under the plasma concentration versus time curve from time 0 to 24 hours (AUC 0-24 [ng·hr/mL]) | Approximately 30 months | ||
Secondary | Area under the plasma concentration versus time curve from time 0 extrapolated to infinity (AUC 0-8 [ng·hr/mL]) | Approximately 30 months | ||
Secondary | Area under the plasma concentration versus time curve over a dosing interval (AUC 0-t [ng·hr/mL]) | Approximately 30 months | ||
Secondary | Maximum plasma concentration (Cmax [ng/mL]) | Approximately 30 months | ||
Secondary | Time of the maximum observed plasma concentration (tmax [hour]) | Approximately 30 months | ||
Secondary | Apparent total clearance (CL/F [L/h]) | Approximately 30 months | ||
Secondary | Apparent volume of distribution during the terminal phase (Vz/F [L]) | Approximately 30 months | ||
Secondary | Apparent terminal elimination half-life (t1/2 [h]) | Approximately 30 months | ||
Secondary | Accumulation ratio based on AUC0-t (AR AUC) | Approximately 30 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04987203 -
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
|
Phase 3 | |
Recruiting |
NCT06391879 -
Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Recruiting |
NCT04623502 -
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
|
N/A | |
Completed |
NCT02853344 -
Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)
|
Phase 2 | |
Terminated |
NCT04088500 -
A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma
|
Phase 2 | |
Completed |
NCT05070637 -
Circulating Tumor Cell Reducing No-touch Nephrectomy
|
N/A | |
Active, not recruiting |
NCT03634540 -
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
|
Phase 2 | |
Not yet recruiting |
NCT06049030 -
A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma
|
Phase 1 | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Completed |
NCT01358721 -
Phase I Biomarker Study (BMS-936558)
|
Phase 1 | |
Active, not recruiting |
NCT04503148 -
Anesthesia and Cancer Study: Renal Cell Carcinoma
|
N/A | |
Completed |
NCT02386826 -
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
|
Phase 1 | |
Not yet recruiting |
NCT05808608 -
A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03323710 -
Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT02787915 -
DC1s-CTL Cellular Therapy for Renal Cell Carcinoma
|
Phase 1/Phase 2 |